Abiopharma

🔍 Stuart Cormac (Executive)

Company: AerCap Holdings N.V. (AER)

Report Date: 2026-06-15

Detailed Transactions and Holdings:

• Sold 11,644 shares of Ordinary Shares at $143.21 per share (Direct)
  Date: 2026-06-15 | Code: S | equity_swap_involved: 0 | transaction_form_type: 4 | Footnotes: F1, F2
• Holds 0 shares of Ordinary Shares (Direct)
  Date: 2026-06-15 | Code: H | nature_of_ownership: By AerCap Approved Profit Sharing Scheme Trust | shares_owned_after: 403.00 | Footnotes: F3
• Holds 0 shares of Ordinary Shares (Direct)
  Date: 2026-06-15 | Code: H | nature_of_ownership: By AerCap Equity Incentive Plans Trust | shares_owned_after: 13,239.00 | Footnotes: F4

Footnotes:

• F1: Includes 11,374 Ordinary Shares that were released from the AerCap Holdings N.V. Equity Incentive Plans Trust since the last Form 4 filed by the Reporting Person on March 26, 2026.
• F2: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $143.12 to $143.69, inclusive. The reporting person undertakes to provide to AerCap Holdings N.V. ("AER"), any security holder of AER or the Staff of the Commission upon request, full information regarding the number of Ordinary Shares sold at each separate price within the ranges set forth herein.
• F3: Represents Ordinary Shares awarded pursuant to equity-based awards that are held in a trust for three years in order to achieve certain tax benefits under Irish law, after which the shares will either be released to the reporting person or sold and the proceeds released to the reporting person.
• F4: Represents Ordinary Shares granted as compensatory awards and held in a trust in order to achieve certain tax benefits under Irish law, after which the shares (to the extent vested) will be released to the reporting person. Of these awards, 4,413 are restricted shares that remain subject to service-based vesting conditions and 8,826 are restricted shares that remain subject to service- and performance-based vesting conditions.